Literature DB >> 19543771

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.

Alfredo A Santillan1, Keith A Delman, Georgia M Beasley, Paul J Mosca, Steven N Hochwald, Stephen R Grobmyer, Robert H Andtbacka, R Dirk Noyes, John M Kane, Merrick I Ross, Douglas S Tyler, Jonathan S Zager.   

Abstract

BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique delivering regional chemotherapy to treat in-transit extremity melanoma. Determining perioperative factors that could predict toxicity is important to optimize strategies to improve clinical outcomes after regional chemotherapy in melanoma.
METHODS: Perioperative factors from 171 ILI patients performed at eight centers from 2001 to 2008 were reviewed. The Wieberdink limb toxicity scale and creatine phosphokinase (CK) levels were used to measure toxicity. Logistic regression analysis was used to estimate the association between toxicity and perioperative parameters.
RESULTS: Mild (grades I-II) and severe (grades >or=III) limb toxicity developed in 68% and 32% of patients, respectively. Melphalan adjusted for ideal body weight (aIBW) and papaverine were used in 47% and 63% of patients, respectively. Median peak CK for all patients was 563 U/l, and median peak occurred at postoperative day 4. On univariate analysis, papaverine and high CK levels (>563 U/l) were significantly associated with higher toxicity. On the contrary, aIBW was significantly associated with a lower risk of severe toxicity. Perfusate blood gas at 30 min [pH, PaO(2), and base excess (BE) ], limb temperature, and ischemia time were not predictive of limb toxicity. On multivariate analysis, severe toxicity was associated with female sex (P = 0.01), papaverine (P = 0.01), and high peak CK levels (P < 0.01). Independent predictors of high CK levels included younger age, unadjusted melphalan dose, and low PaO(2) at 30 min.
CONCLUSIONS: ILI can be performed with an acceptable morbidity. Papaverine use, female gender, and high peak CK were associated with higher limb toxicity. CK levels can be diminished significantly with aIBW.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543771     DOI: 10.1245/s10434-009-0563-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

2.  Quality of life after isolated limb infusion for in-transit melanoma of the extremity.

Authors:  Betty S Jiang; Paul J Speicher; Samantha Thomas; Paul J Mosca; Amy P Abernethy; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2014-08-14       Impact factor: 5.344

3.  A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Authors:  Georgia M Beasley; Paul Speicher; Christina K Augustine; Paul C Dolber; Bercedis L Peterson; Ketan Sharma; Paul J Mosca; Richard Royal; Merrick Ross; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2014-08-22       Impact factor: 5.344

4.  Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.

Authors:  Kiran K Turaga; Georgia M Beasley; John M Kane; Keith A Delman; Stephen R Grobmyer; Ricardo J Gonzalez; G Douglas Letson; David Cheong; Douglas S Tyler; Jonathan S Zager
Journal:  Arch Surg       Date:  2011-07

Review 5.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

Review 6.  Regional treatment strategies for in-transit melanoma metastasis.

Authors:  Ryan S Turley; Amanda K Raymond; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

Review 7.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

8.  Isolated limb infusion in a series of over 100 infusions: a single-center experience.

Authors:  Joyce Wong; Y Ann Chen; Kate J Fisher; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

9.  The use of isolated limb infusion in limb threatening extremity sarcomas.

Authors:  Nasreen A Vohra; Kiran K Turaga; Ricardo J Gonzalez; Anthony Conley; Damon Reed; Marilyn M Bui; David Cheong; Douglas G Letson; Jonathan S Zager
Journal:  Int J Hyperthermia       Date:  2012-12-03       Impact factor: 3.914

10.  Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.

Authors:  Joyce Wong; Y Ann Chen; Kate J Fisher; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2013-10-26       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.